Concepedia

Author

H. Nüßlein

Schlosspark-Klinik

Also Known As

A. O'Brien, H G Nusslein, H G NÜSSLEIN, H G Nüsslein, H Nüsslein, H Nüßlein, H. G. NÜSSLEIN, H. G. Nüsslein, H. G. Nüßlein, H. Michels

101

Publications

1.3K

Citations

21

H-Index

5

Concepts

All Affiliations

Schlosspark-KlinikBristol-Myers Squibb (Germany)University of SienaUniversity Hospital HeidelbergBristol-Myers Squibb (France)
HN

About

H. Nüßlein is an author at Schlosspark-Klinik specializing in inflammatory arthritis, medicine, and rheumatology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

29

2

Rheumatology

1

1

29

3

Inflammatory Arthritis

1

1

29

4

Rheumatic Diseases

1

1

29

5

Gout

1

1

29

H. Nüßlein

×

9

Publications

299

Citations

9

H-Index

YearCitations

Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study

H. Nüßlein, Rieke Alten, Mauro Galeazzi,

BMC Musculoskeletal Disorders

2014

49

Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study

Rieke Alten, H. Nüßlein, Xavier Mariette,

RMD Open

2017

43

Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study

H. Nüßlein, Rieke Alten, Mauro Galeazzi,

BMC Musculoskeletal Disorders

2015

41

Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study

Rieke Alten, Xavier Mariette, Hanns‐Martin Lorenz,

Clinical Rheumatology

2019

34

Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study.

H. Nüßlein, Rieke Alten, Mauro Galeazzi,

PubMed

2016

32

[Full version of the S2e guidelines on gouty arthritis : Evidence-based guidelines of the German Society of Rheumatology (DGRh)].

Uta Kiltz, Rieke Alten, Marcelo P. Fleck,

PubMed

2016

29

Real-world predictors of 12–month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study

Rieke Alten, Xavier Mariette, Hanns‐Martin Lorenz,

RMD Open

2017

29

Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study

Rieke Alten, H. Nüßlein, Mauro Galeazzi,

RMD Open

2016

21

The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study

Xavier Mariette, Rieke Alten, H. Nüßlein,

Joint Bone Spine

2016

21

Page 1